Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Boehringer Ingelheim
Baxter
Harvard Business School
Merck

Last Updated: August 11, 2022

RAYOS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Rayos patents expire, and what generic alternatives are available?

Rayos is a drug marketed by Horizon and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-three patent family members in twenty-nine countries.

The generic ingredient in RAYOS is prednisone. There are sixteen drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the prednisone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rayos

A generic version of RAYOS was approved as prednisone by WATSON LABS on December 31st, 1969.

  Try it Free

Paragraph IV (Patent) Challenges for RAYOS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RAYOS Delayed-release Tablets prednisone 1 mg, 2 mg, and 5 mg 202020 1 2012-11-26

US Patents and Regulatory Information for RAYOS

RAYOS is protected by seven US patents.

Patents protecting RAYOS

Delayed release tablet with defined core geometry
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY,GASTROINTESTINAL,DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET

Delayed release tablet with defined core geometry
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET

Delayed release tablet with defined core geometry
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Delayed release tablet with defined core geometry
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Delayed release tablet with defined core geometry
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Delayed release tablet with defined core geometry
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Delayed-release glucocorticoid treatment of rheumatoid disease
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-003 Jul 26, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-003 Jul 26, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-003 Jul 26, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RAYOS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 See Plans and Pricing See Plans and Pricing
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 See Plans and Pricing See Plans and Pricing
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 See Plans and Pricing See Plans and Pricing
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for RAYOS

See the table below for patents covering RAYOS around the world.

Country Patent Number Title Estimated Expiration
Canada 2422991 See Plans and Pricing
Mexico PA05011446 TABLETA CON LIBERACION RETARDADA CON GEOMETRIA DE NUCLEO DEFINIDA. (DELAYED RELEASE TABLET WITH DEFINED CORE GEOMETRY.) See Plans and Pricing
Portugal 1631251 See Plans and Pricing
Norway 20090958 See Plans and Pricing
South Korea 20060015528 DELAYED RELEASE TABLET WITH DEFINED CORE GEOMETRY See Plans and Pricing
World Intellectual Property Organization (WIPO) 0054780 See Plans and Pricing
European Patent Office 1318816 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Merck
Harvard Business School
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.